Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.
about
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitorsRegulatory T cells and immune tolerance to coagulation factor IX in the context of intramuscular AAV1 gene transfer.Physical and psychosocial challenges in adult hemophilia patients with inhibitors.Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa.Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.Treatment of hemophilia: a review of current advances and ongoing issuesModulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of HemophiliaEconomic burden of high-responding inhibitors in patients with hemophilia A in Taiwan.Inhibitor development in haemophilia B: an orphan disease in need of attention.Inherited disorders of blood coagulation.Pharmacotherapy of haemophilia A.Clinical advances in hemophilia management.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.Recommendations for assessment, monitoring and follow-up of patients with haemophilia.Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States.Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review.Impact of haemophilia with inhibitors on caregiver burden in the United States.Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.Animal models of FVIIa gene expression: their role in the future development of haemophilia treatmentCost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics.Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects.Prophylaxis and treatment of chronic synovitis in haemophilia patients with inhibitors.On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).Efficacy and safety of OCTANINE F in children with haemophilia B.Haemophilic arthropathy from A to Z. Introduction.Guidelines for the management of hemophilia.Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.Haemophilia and joint disease: pathophysiology, evaluation, and management.Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
P2860
Q24187021-BF7BB140-447C-45D4-959D-719E96ABA4F0Q33730693-DCCD00AD-59F2-4CFC-8E3A-0E45915593ADQ33968730-CB126AAC-9CA1-4AF2-8D99-3E0FDECBE26CQ34999749-32C8856B-3CEA-44DD-AF2E-DA27BB4DC92DQ35007278-8100684C-684A-4B28-BBD5-7B1B6A4A7A94Q35683781-469FE706-ECA1-4A48-A468-576C3119A57AQ36007714-0893E89C-27D9-4544-B997-77F1313072F8Q36019034-512876A4-C505-487E-8A10-CD2400F52921Q36196486-DCABBDF8-43D3-41C3-8944-7187183DE759Q36620369-3ACF6A39-4297-40C2-99C9-B3F0C463726CQ36872038-E22D7775-D1DB-4628-99C5-EBBF31CC52A1Q37876411-0EA1BEE1-C641-427E-9835-7161E771C32EQ37891089-8DFBC4CA-BDCB-412C-8FCF-F70C9D86B56EQ37900933-A42BAFCB-3BE7-4AA6-AE14-B68941B63E39Q37927122-C025F9E1-5FD4-4ACC-A4AA-7560ABD698BDQ37944947-70F964BB-751D-4113-BC40-2BE91219D5F5Q38182706-FB81F95F-61FF-48D6-B89F-8AF6D0F5E526Q38212494-7E66446A-C85C-4B97-A04D-AE98573AA8B7Q38255934-F403BECC-7D9E-4EE9-8B6A-2EE5135807F8Q38513393-D319F1A8-90D5-4482-9275-2FCCB719E09FQ39261141-0DE5926E-D3E3-4E56-80B5-7FF3278C24E9Q39898071-6C84EAC5-E6E7-4D5A-8F28-C0791E60594FQ41099388-C6A28DF7-9CFD-4BD9-BF77-B8AAD042A222Q41673270-B3E69857-1B69-4378-9FE0-9855F8122876Q42692841-89688994-D997-4FF2-ADE9-78A6AD9E51FDQ45857838-211EFA07-3154-47C7-9B9A-7FCEFE467E58Q45865143-D54C273D-4DBA-4D99-83D5-D24625FE3351Q45870073-19DDCC4A-7C17-42D9-88D0-FD28219ABA75Q45870800-C1ED966A-53BD-4D54-8CAA-E579E50EC9D3Q45871901-E0AF7095-393E-402C-8B19-6DFB93319BA4Q45872129-47BE1FB0-D547-469F-96D0-82A4F001A7B0Q45873491-9BDF7F04-6D95-464B-BA90-6F41BD7119D4Q45873687-1BDA02AD-CA39-4D2D-B9C7-83A58CB07CCBQ45875884-F03A4D83-F7F6-4927-A2CD-7883F484BEC3Q45876094-9A8DB9D1-9F62-4C86-85D5-45CCAB82AF5EQ45877688-C91DAD99-9B25-49E0-88E7-A6B094F188CEQ45880345-1C8F6F31-C032-4A24-8421-6AC693EB54ABQ45887994-EF8DDFFE-BDCC-482A-B95C-DCB9ED42E28DQ55004994-B89C0EBB-DE7A-4A0F-8C77-50EEFE8BF9AEQ57179210-1D3DA97D-C7DA-4E58-9BB4-C88677121114
P2860
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Inhibitor treatment in haemoph ...... national consensus conference.
@ast
Inhibitor treatment in haemoph ...... national consensus conference.
@en
type
label
Inhibitor treatment in haemoph ...... national consensus conference.
@ast
Inhibitor treatment in haemoph ...... national consensus conference.
@en
prefLabel
Inhibitor treatment in haemoph ...... national consensus conference.
@ast
Inhibitor treatment in haemoph ...... national consensus conference.
@en
P2093
P1433
P1476
Inhibitor treatment in haemoph ...... national consensus conference.
@en
P2093
Astermark J
Berntorp E
Blanchette VS
Collins PW
Dimichele D
Escuriola C
Leissinger CA
P356
10.1111/J.1365-2516.2006.01359.X
P478
12 Suppl 6
P577
2006-12-01T00:00:00Z